Compare VOR & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VOR | CERT |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 813.3M | 808.9M |
| IPO Year | 2021 | 2020 |
| Metric | VOR | CERT |
|---|---|---|
| Price | $15.60 | $5.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $45.33 | $11.67 |
| AVG Volume (30 Days) | 866.9K | ★ 4.0M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $418,838,000.00 |
| Revenue This Year | N/A | $4.18 |
| Revenue Next Year | N/A | $5.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $1.11 | $4.45 |
| 52 Week High | $49.95 | $13.88 |
| Indicator | VOR | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 57.90 | 55.12 |
| Support Level | $11.95 | $5.08 |
| Resistance Level | $16.87 | $6.34 |
| Average True Range (ATR) | 0.96 | 0.35 |
| MACD | 0.19 | 0.03 |
| Stochastic Oscillator | 81.35 | 60.16 |
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.